“If I have ever made any valuable discoveries, it has been owing more to patient attention, than to any other talent.”
Novel biologics for
diseases with unmet need
Novel biologics for
diseases with unmet need
Technology
Our Toolbox
By utilizing multiple complementary platform technologies, Forbius engineers proprietary, fit-for-purpose biotherapeutics positioned to
become the new standard of care. Our strength is designing highly active inhibitors of validated pathways that have a differentiated
mechanism of action.
- Traps
- mAbs
- ADCs
- In Silico
Receptor ectodomain-based traps
Forbius uses receptor ectodomain-based trap technology to design selective and potent traps that neutralize ligands that are over-expressed in disease. We have a unique approach to designing traps that results in superior potency compared to traditional trap engineering approaches.
Monoclonal antibodies
Forbius uses novel immunization and screening approaches to enable identification of unique monoclonal antibodies (mAbs) with desired activities.
Antibody-drug conjugates
Forbius utilizes antibody-drug conjugate (ADC) technology to enhance the activity of antibodies targeting internalizing cell surface proteins that are over-expressed in disease.
In Silico
Forbius utilizes cutting-edge in silico protein modelling platforms to accelerate and optimize design of its biotherapeutics.
Careers
Working at Forbius
Forbius is a rapidly growing, science-driven company. We are pleased to hear from individuals with a track-record of achievement who are interested in joining our team. Click here to learn more about our corporate culture and open positions.
